Form 4 for FDMT 4D Molecular Therapeutics, Inc.
Accepted 2022-12-05 00:00:00 ET · period of report 2022-12-01 · accession 0001567619-22-021291 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-12-05 | 2022-12-01 | FDMT | Bizily Scott | Chief Legal, HR Off | S - Sale+OE | $22.79 | -6,000 | 4,332 | -58% | -$136.7K |
| DM | 2022-12-05 | 2022-12-01 | FDMT | Bizily Scott | Chief Legal, HR Off | M - OptEx | $7.52 | +5,625 | 4,732 | New | +$42.3K |
| DM | 2022-12-05 | 2022-12-01 | FDMT | Bizily Scott | Chief Legal, HR Off | M - OptEx | $0.00 | -5,625 | 56.2K | -9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-01 | S | D | 375 | $24.35 | 2,482 | D | — | — | |
| 2 | Common | Common Stock | 2022-12-01 | S | D | 100 | $24.49 | 2,857 | D | — | — | |
| 3 | Common | Common Stock | 2022-12-01 | S | D | 200 | $23.44 | 2,957 | D | — | — | |
| 4 | Common | Common Stock | 2022-12-01 | S | D | 2,450 | $22.93 | 3,157 | D | — | — | (F6) The transaction was executed in multiple trades in prices ranging from $22.39 to $23.36, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 5 | Common | Common Stock | 2022-12-01 | S | D | 1,000 | $21.78 | 5,607 | D | — | — | (F5) The transaction was executed in multiple trades in prices ranging from $21.21 to $22.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 6 | Common | Common Stock | 2022-12-01 | M | A | 3,750 | $8.04 | 6,607 | D | — | — | |
| 7 | Common | Common Stock | 2022-12-01 | S | D | 100 | $24.49 | 2,857 | D | — | — | |
| 8 | Common | Common Stock | 2022-12-01 | S | D | 400 | $23.25 | 2,957 | D | — | — | (F4) The transaction was executed in multiple trades in prices ranging from $23.16 to $23.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 9 | Common | Common Stock | 2022-12-01 | S | D | 975 | $22.71 | 3,357 | D | — | — | (F3) The transaction was executed in multiple trades in prices ranging from $22.13 to $23.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 10 | Common | Common Stock | 2022-12-01 | M | A | 1,875 | $6.49 | 4,732 | D | — | — | (F9) Reflects 2,857 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. |
| 11 | Common | Common Stock | 2022-12-01 | S | D | 400 | $21.52 | 4,332 | D | — | — | (F2) The transaction was executed in multiple trades in prices ranging from $20.92 to $21.79, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 12 | Derivative | Stock Option (Right to Buy) | 2022-12-01 | M | D | 1,875 | $0.00 | 22,125 | D | $6.49 · — to 2032-06-17 | 1,875 Common Stock | (F7) The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |
| 13 | Derivative | Stock Option (Right to Buy) | 2022-12-01 | M | D | 3,750 | $0.00 | 56,250 | D | $8.04 · — to 2032-08-31 | 3,750 Common Stock | (F8) The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |